Kazia Therapeutics EV / EBITDA
Cos'è EV / EBITDA di Kazia Therapeutics?
EV / EBITDA di Kazia Therapeutics Limited è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con ev / ebitda simili a Kazia Therapeutics
- NeonMind Biosciences ha EV / EBITDA di N/A
- Lumos Diagnostics ha EV / EBITDA di N/A
- Bluewater Acquisition Corp ha EV / EBITDA di N/A
- Guyana Goldstrike Inc ha EV / EBITDA di N/A
- BrewBilt Manufacturing ha EV / EBITDA di N/A
- Sable Resources ha EV / EBITDA di N/A
- Kazia Therapeutics ha EV / EBITDA di N/A
- engage:BDR ha EV / EBITDA di N/A
- Viaan Industries ha EV / EBITDA di N/A
- Antera Ventures Ii Corp ha EV / EBITDA di N/A
- MacDonald Mines Exploration ha EV / EBITDA di N/A
- Sihayo Gold ha EV / EBITDA di N/A
- Fabled Copper ha EV / EBITDA di N/A